drugset / Trial / NCT05320575
Zanubrutinib for HLH
NaSingle-groupOpen-labelTreatment
Summary
This study is a prospective single-arm clinical study, focusing on Hemophagocytic lymphohistocytosis，to evaluate the clinical efficacy and safety of zanubrutinib.
Timeline
- Start
- 2022-02-01
- Primary completion
- 2023-08-01
- Completion
- 2023-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zanubrutinib | Small molecule | 80 mg | — |
| Subject | Zanubrutinib | Small molecule | 160 mg | — |